Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Crabb

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|March 9, 2020
Treatment of upper urinary tract urothelial carcinomaSimon J Crabb
European Urology|April 1, 2019
Personalised Medicine for Advanced Urothelial Cancer: What is the Right Way to Identify the Right Patient for the Right Treatment?Simon J Crabb
European Urology|July 19, 2018
Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the TableSimon J Crabb
British Medical Bulletin|October 30, 2018
The latest treatment options for bladder cancerSimon J Crabb, James Douglas
Research and Reports in Urology|July 13, 2023
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved OutcomesMegan Giles, Simon J Crabb
Cancer Medicine|June 22, 2018
Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancerBradleigh Whitton, Haruko Okamoto, Graham Packham, et al.
Oncology Reports|February 22, 2008
BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cellsSimon J Crabb, Angela Hague, Peter W M Johnson, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and SafetySimon J Crabb, Taha Khalid, Lois Woods, et al.
Breast Cancer Research and Treatment|June 18, 2010
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibitionAnnette Hayden, Peter W M Johnson, Graham Packham, et al.
Molecular Cancer Therapeutics|February 10, 2021
V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate CancerBradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|March 9, 2020
Treatment of upper urinary tract urothelial carcinomaSimon J Crabb
European Urology|April 1, 2019
Personalised Medicine for Advanced Urothelial Cancer: What is the Right Way to Identify the Right Patient for the Right Treatment?Simon J Crabb
European Urology|July 19, 2018
Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the TableSimon J Crabb
British Medical Bulletin|October 30, 2018
The latest treatment options for bladder cancerSimon J Crabb, James Douglas
Research and Reports in Urology|July 13, 2023
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved OutcomesMegan Giles, Simon J Crabb
Cancer Medicine|June 22, 2018
Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancerBradleigh Whitton, Haruko Okamoto, Graham Packham, et al.
Oncology Reports|February 22, 2008
BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cellsSimon J Crabb, Angela Hague, Peter W M Johnson, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and SafetySimon J Crabb, Taha Khalid, Lois Woods, et al.
Breast Cancer Research and Treatment|June 18, 2010
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibitionAnnette Hayden, Peter W M Johnson, Graham Packham, et al.
Molecular Cancer Therapeutics|February 10, 2021
V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate CancerBradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, et al.
Pageof 9